Evidence map›Paper›PMID 42352279›Full record

ArticleBiomolecules2026

STY12, a Novel NQO1/HDAC Dual-Targeting Agent, Exhibits Potent Anti-Pancreatic Cancer Activity by ROS-Mediated DNA Damage.

Tong Shen, Xiaojuan Yang, Zhenhua Han, Yanjie Dong, Liqiang Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tong ShenSchool of Pharmacy, Henan Medical University, Xinxiang 453003, China.
Xiaojuan YangSchool of Pharmacy, Xinxiang University, Xinxiang 453003, China.
Zhenhua HanSchool of Pharmacy, Henan Medical University, Xinxiang 453003, China.
Yanjie DongWest China School of Medicine, Sichuan University, Chengdu 610041, China.ORCID 0000-0002-5461-4951
Liqiang WuSchool of Pharmacy, Henan Medical University, Xinxiang 453003, China.

Funding

Henan Academy of Sciences 252300420144
6 · The paper itself

Abstract

Pancreatic cancer (PC) usually results in poor survival with limited treatment options. Reactive oxygen species (ROS) play a key role in the action of HDAC inhibitors. In combination with a ROS generator, it can increase sensitivity to HDAC inhibitors and also overcome resistance to HDAC inhibitors. NQO1-bioactivatable drugs are efficient ROS generators. Therefore, to reduce HDAC inhibitor resistance and enhance its anti-pancreatic cancer activity, in this study, we reported a novel NQO1/HDAC dual-targeting agent,

Indexed as

Antineoplastic AgentsDNA DamageHistone Deacetylase InhibitorsNAD(P)H Dehydrogenase (Quinone)Pancreatic NeoplasmsReactive Oxygen SpeciesAcetylationAnimalsApoptosisCell Line, TumorCell ProliferationHistone Deacetylase 1Histone Deacetylase 6Histone DeacetylasesHumansMiceAntineoplastic AgentsHDAC1 protein, humanHistone Deacetylase 1Histone Deacetylase 6Histone Deacetylase InhibitorsHistone DeacetylasesNAD(P)H Dehydrogenase (Quinone)NQO1 protein, humanReactive Oxygen SpeciesantitumorHDACNQO1pancreatic cancerROS

Identifiers

PMID42352279
PMCPMC13296467

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.